AstraZeneca PLC (LON:AZN) Given Average Recommendation of “Moderate Buy” by Analysts

AstraZeneca PLC (LON:AZN) has earned an average recommendation of “Moderate Buy” from the seven analysts that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is GBX 7,542.80 ($97.65).

A number of research firms have commented on AZN. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Friday, March 7th. Berenberg Bank reissued a “buy” rating and issued a GBX 140 ($1.81) price objective on shares of AstraZeneca in a research note on Monday, January 27th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research note on Wednesday, February 19th.

AstraZeneca Stock Down 0.9 %

LON AZN opened at £113.52 ($146.97) on Friday. AstraZeneca has a 52 week low of GBX 9,670 ($125.19) and a 52 week high of £133.88 ($173.33). The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. The company has a market capitalization of £218.42 billion, a P/E ratio of 31.12, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The stock’s 50-day moving average price is £115.59 and its 200-day moving average price is £112.95.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.